Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia
· Delayed Price · Currency is MYR 1.390
-0.110 (-7.33%)
At close: Mar 9, 2026
Duopharma Biotech Berhad Ratios and Metrics
Market cap in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 1,337 | 1,202 | 1,202 | 1,212 | 1,533 | 1,582 | Upgrade
|
| Market Cap Growth | 12.10% | - | -0.79% | -20.94% | -3.10% | -33.70% | Upgrade
|
| Enterprise Value | 1,542 | 1,428 | 1,469 | 1,522 | 1,819 | 1,881 | Upgrade
|
| Last Close Price | 1.39 | 1.25 | 1.22 | 1.20 | 1.50 | 1.55 | Upgrade
|
| PE Ratio | 15.29 | 13.75 | 19.19 | 23.02 | 21.87 | 24.09 | Upgrade
|
| Forward PE | 13.24 | 12.08 | 14.74 | 14.77 | 15.91 | 20.97 | Upgrade
|
| PS Ratio | 1.44 | 1.29 | 1.48 | 1.72 | 2.20 | 2.48 | Upgrade
|
| PB Ratio | 1.76 | 1.59 | 1.70 | 1.76 | 2.34 | 2.54 | Upgrade
|
| P/TBV Ratio | 1.86 | 1.67 | 1.71 | 1.78 | 2.35 | 2.56 | Upgrade
|
| P/FCF Ratio | 16.70 | 15.02 | 20.12 | 76.43 | 301.61 | - | Upgrade
|
| P/OCF Ratio | 12.52 | 11.26 | 14.43 | 24.84 | 21.82 | 36.62 | Upgrade
|
| PEG Ratio | 0.37 | 0.61 | 0.72 | 12.31 | 1.10 | 4.11 | Upgrade
|
| EV/Sales Ratio | 1.66 | 1.53 | 1.81 | 2.16 | 2.61 | 2.94 | Upgrade
|
| EV/EBITDA Ratio | 8.59 | 7.96 | 10.70 | 13.35 | 14.80 | 16.36 | Upgrade
|
| EV/EBIT Ratio | 11.52 | 10.67 | 14.66 | 19.34 | 19.57 | 21.19 | Upgrade
|
| EV/FCF Ratio | 19.25 | 17.83 | 24.59 | 95.99 | 357.77 | - | Upgrade
|
| Debt / Equity Ratio | 0.65 | 0.65 | 0.73 | 0.80 | 0.66 | 0.65 | Upgrade
|
| Debt / EBITDA Ratio | 2.76 | 2.76 | 3.66 | 4.67 | 3.41 | 3.41 | Upgrade
|
| Debt / FCF Ratio | 6.19 | 6.19 | 8.63 | 34.61 | 84.91 | - | Upgrade
|
| Net Debt / Equity Ratio | 0.27 | 0.27 | 0.35 | 0.41 | 0.42 | 0.43 | Upgrade
|
| Net Debt / EBITDA Ratio | 1.14 | 1.14 | 1.83 | 2.44 | 2.23 | 2.31 | Upgrade
|
| Net Debt / FCF Ratio | 2.56 | 2.56 | 4.20 | 17.55 | 53.90 | -4.02 | Upgrade
|
| Asset Turnover | 0.66 | 0.66 | 0.60 | 0.55 | 0.58 | 0.57 | Upgrade
|
| Inventory Turnover | 2.10 | 2.10 | 2.08 | 1.83 | 1.82 | 2.06 | Upgrade
|
| Quick Ratio | 1.68 | 1.68 | 2.65 | 2.59 | 1.13 | 1.18 | Upgrade
|
| Current Ratio | 2.61 | 2.61 | 4.08 | 4.06 | 2.05 | 2.15 | Upgrade
|
| Return on Equity (ROE) | 11.93% | 11.93% | 8.97% | 7.84% | 10.96% | 10.36% | Upgrade
|
| Return on Assets (ROA) | 5.92% | 5.92% | 4.60% | 3.83% | 4.87% | 4.99% | Upgrade
|
| Return on Invested Capital (ROIC) | 10.54% | 10.59% | 8.15% | 6.91% | 8.44% | 8.37% | Upgrade
|
| Return on Capital Employed (ROCE) | 11.80% | 11.80% | 8.40% | 6.70% | 9.70% | 9.50% | Upgrade
|
| Earnings Yield | 6.54% | 7.27% | 5.21% | 4.34% | 4.57% | 4.15% | Upgrade
|
| FCF Yield | 5.99% | 6.66% | 4.97% | 1.31% | 0.33% | -4.18% | Upgrade
|
| Dividend Yield | 3.03% | 3.64% | 2.47% | 1.92% | 1.53% | 1.41% | Upgrade
|
| Payout Ratio | 38.49% | 38.49% | 42.99% | 16.81% | 11.70% | 68.45% | Upgrade
|
| Buyback Yield / Dilution | - | - | -0.36% | -1.08% | -2.15% | -0.02% | Upgrade
|
| Total Shareholder Return | 3.03% | 3.64% | 2.11% | 0.85% | -0.62% | 1.39% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.